Calithera biosciences, inc. (CALA)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Cash Flows Used in Operating Activities
Net loss

-89,860

-54,629

-27,826

-38,004

-

-

-

-

Net loss

-

-

-

-

-32,644

-21,712

-12,377

-7,975

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

479

505

365

297

-

-

-

-

Amortization of premiums on investments

897

272

-446

-590

-

-

-

-

Depreciation and amortization

-

-

-

-

404

361

281

269

Amortization of premiums on investments

-

-

-

-

446

-

-

-

Stock-based compensation

6,466

7,437

5,536

4,250

3,272

689

70

31

Loss on disposal of property and equipment

-

-

-9

-

7

-2

-5

-7

Non-cash lease expense

1,366

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Receivables from collaborations

-1,515

855

1,142

-

-

-

-

-

Prepaid expenses and other current assets

26

-630

952

-787

673

1,544

282

9

Other assets

-289

341

-62

9

263

-

-

-

Accounts payable

816

175

674

-28

-131

543

125

25

Accrued liabilities

2,576

4,725

4,878

925

-196

2,058

310

675

Lease liability

1,469

-

-

-

-

-

-

-

Deferred revenue

-

-22,254

31,045

-

-

-

-

-

Deferred rent

-

-

-

167

-141

-

-

-

Deferred rent, non-current

-

37

656

-

-

372

31

-13

Net cash used in operating activities

-78,745

-64,842

13,751

-31,025

-

-

-

-

Cash Flows (Used in) Provided by Investing Activities
Net cash provided by (used in) operating activities

-

-

-

-

-29,933

-19,231

-11,837

-6,990

Purchases of investments

153,227

76,107

194,650

44,618

109,099

-

-

-

Proceeds from sale and maturity of investments

142,450

129,120

97,448

68,724

42,764

-

-

-

Purchases of property and equipment

7

214

1,229

401

441

556

164

49

Net cash (used in) provided by investing activities

-10,784

52,799

-98,431

23,705

-

-

-

-

Cash Flows Provided by Financing Activities
Proceeds from issuance of common stock upon public offering, net

53,760

-

75,386

-

-

-

-

-

Change in restricted cash

-

-

-

-

-

-70

9

-

Net cash provided by (used in) investing activities

-

-

-

-

-66,776

-486

-173

-49

Proceeds from issuance of common stock upon public offering, net

-

-

-

-

-

71,625

-

-

Proceeds from issuance of common stock under stock purchase agreement, net

-

-

7,914

-

-

-

-

-

Proceeds from issuance of common stock through an at-the-market offering, net

43,926

13,705

38,315

11,281

-

-

-

-

Proceeds from stock option exercises

-

-

-

-

-

-

-

3

Proceeds from issuance of convertible preferred stock, net

-

-

-

-

-

15,959

43,560

5,963

Proceeds from stock option exercises and employee stock plan purchases

1,222

921

1,333

535

845

282

65

-

Net cash provided by financing activities

98,908

14,626

122,948

11,816

-

-

-

-

Net cash provided by financing activities

-

-

-

-

845

87,866

43,625

5,966

Net decrease in cash, cash equivalents, and restricted cash

9,379

2,583

38,268

4,496

-

-

-

-

Supplemental Disclosure of Non-Cash Financing Information:
Net increase (decrease) in cash and cash equivalents

-

-

-

-

-95,864

68,149

31,615

-1,073

Supplemental Disclosure of Non-Cash Activities:
Unpaid amounts related to property and equipment purchases

-

-

-

-

26

110

-

-

Unpaid amounts related to deferred financing costs

68

25

-

-

-

-

-

-

Services settled through the issuance of common stock

-

-

-

-

-

55

-

-

Conversion of preferred stock warrants to common stock warrants

-

-

-

-

-

-

-

41

Gain on extinguishment of convertible preferred stock

-

-

-

-

-

-

-

2,889